Characterisation of a novel transcript LNPPS acting as tumour suppressor in bladder cancer via PDCD5‐mediated p53 degradation blockage
Clinical and Translational Medicine · 2023
DOI: 10.1002/ctm2.1149 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Medicine, 2023. Verfasst von Juan Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China. Hauptthemen laut MEDLINE: RNA, Long Noncoding, Urinary Bladder Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Key Technology Research and Development Program of Shandong, Natural Science Foundation of Shandong Province.
Abstract (Originalsprache)
Background
Long non‐coding RNAs (lncRNAs) play a crucial role in tumour initiation and progression. However, little is known about their contributions to p53‐related bladder cancer (BC) inhibition.
Methods
By using high‐throughput sequencing, we screened the expression profiles of lncRNAs in BC and adjacent non‐tumour tissues. The roles of a novel lncRNA, named LNPPS [a lncRNA for programmed cell death 5 (PDCD5) and p53 stability], were determined by gain‐ and loss‐of‐function assays. RNA pull‐down followed by mass spectrometry analysis, RNA immunoprecipitation assays and other immunoprecipitation assays were performed to reveal the interactions among LNPPS, PDCD5 and p53, and the regulatory effect of LNPPS on the complex ubiquitination network comprising PDCD5, p53 and mouse double minute 2 homologue (MDM2).
Results
LNPPS was downregulated in BC and markedly inhibited the viability of BC cells by inducing PDCD5/p53‐related apoptosis in vivo and in vitro. Mechanistically, LNPPS, serving as a scaffold, connected PDCD5 and p53 with nucleotides (nt) located at 121‒251 nt and 251‒306 nt of LNPPS, respectively. This process allowed LNPPS to protect PDCD5 from proteasomal degradation by blocking its K20 site ubiquitination. On the other hand, the increased interaction between PDCD5 and p53 displaced p53 from the MDM2‒p53 ubiquitination complex, resulting in an increase in p53 expression and related apoptosis levels. Moreover, LNPPS could induce the accumulation of PDCD5 and p53 in the nucleus and exert a synergistic effect on the prevention of protein degradation. In addition, we confirmed that the downregulation of LNPPS in BC was mediated by the decreased N6‐methyladenosine (m 6 A) modification.
Conclusion
Our findings highlight a novel cross‐talk between LNPPS and the PDCD5/p53/MDM2 ubiquitination axis in BC development, indicating its potential as a therapeutic target for BC patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Laboratory, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, Shandong, China.
- Shandong Engineering & Technology Research Center for Tumor Marker Detection, Jinan, Shandong, China.
- Shandong Provincial Clinical Medicine Research Center for Clinical Laboratory, Jinan, Shandong, China.
Förderung
- National Natural Science Foundation of China
- Key Technology Research and Development Program of Shandong
- Natural Science Foundation of Shandong Province
Zitieren
APA
Li, J., Wang, Y., Zhang, X., Yang, X., Qi, Q., Mi, Q., Feng, M., Wang, Y., Wang, C., Li, P., & Du, L. (2023). Characterisation of a novel transcript LNPPS acting as tumour suppressor in bladder cancer via PDCD5‐mediated p53 degradation blockage. Clinical and Translational Medicine. https://doi.org/10.1002/ctm2.1149
Vancouver
Li J, Wang Y, Zhang X, Yang X, Qi Q, Mi Q, et al. Characterisation of a novel transcript LNPPS acting as tumour suppressor in bladder cancer via PDCD5‐mediated p53 degradation blockage. Clinical and Translational Medicine. 2023. doi:10.1002/ctm2.1149
BibTeX
@article{Li2023,
author = {Li, Juan and Wang, Yifan and Zhang, Xinya and Yang, Xuemei and Qi, Qiuchen and Mi, Qi and Feng, Maoxiao and Wang, Yunshan and Wang, Chuanxin and Li, Peilong and Du, Lutao},
title = {Characterisation of a novel transcript LNPPS acting as tumour suppressor in bladder cancer via PDCD5‐mediated p53 degradation blockage},
journal = {Clinical and Translational Medicine},
year = {2023},
doi = {10.1002/ctm2.1149}
}
EUVIMED